1. 1-School of Advanced Technologies in Medicine, Department of Biotechnology and Molecular Medicine, faculty of Medicine, 2. 1-School of Advanced Technologies in Medicine, Department of Biotechnology and Molecular Medicine, faculty of Medicine, 3. - Nanotechnology Center, BuAli Research Institute, Mashhad University of Medical Sciences
Abstract
Introduction
Rheumatoid arthritis (ra) is a chronic, systemic, immune-mediated inflammatory disease associated with decreased life expectancy and quality of life. ra is characterized by chronic inflammation and synovial hyperplasia leading to destruction of cartilage and bone. tumour necrosis factor (tnf) is a pro-inflammatory cytokine that signals through two distinct receptors, tnfr1 and tnfr2. tnf is essentially involved in the pathogenesis of various inflammatory and autoimmune diseases. blocking tnf, in turn, has been proven to be highly effective in treating a variety of diseases. the aim of this study is to investigate the protective effect of the recombinant humantnfr2 on collagen-induced arthritis in mice.
Methods
: cia was induced in female balb/c mice by been subcutaneously injected type ii bovine collagen (cii) for twice. after the second collagen immunization, mice were administered with recombinant tnfr2 (1 mg/kg) every other day for 2 weeks. the progression of edema of paws and knee joints was inspected by using a vernier calliper every 3 days from the 21th day after the first injection to the end of the experiment.the knee joint destruction was observed by pathological sections.
Results
Administration of recombinant human tnfr2 significantly suppressed paws and joints swelling . pathological examination demonstrated that recombinant protein effectively protected ankle bone and cartilage from being eroded versus treated mice.
Conclusion
Our studies demonstrate that administration of recombinant protein is obviously suppressed the progression of cia. the anti-arthritic effectiveness of recombinant tnfr will make the a strong candidate for further clinical trials on ra patients
